Clinical trial NCT06994598: Investigation of Respiratory Muscle Sarcopenia in Geriatric Individuals
Official title: Investigation of Respiratory Muscle Sarcopenia in Geriatric Individuals
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Geriatric
Sarcopenia
Diaphragm
Lead sponsor: Kirsehir Ahi Evran Universitesi
Sponsor class: OTHER
First posted: 2025-05-29
Enrollment: 85
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Volunteers aged 65 and over.

Brief summary: The increase in the elderly population worldwide necessitates further research on age-related physiological changes and health problems related to these changes in geriatric individuals. One of these problems, sarcopenia, is a syndrome characterized by a decrease in muscle mass, muscle strength, and physical performance due to aging (Cruz-Jentoft et al., 2019). Sarcopenia affects not only the extremity muscles but also the respiratory muscles, significantly reducing the individual's functional capacity and quality of life (Shafiee et al., 2017). Sarcopenia is a progressive and widespread loss of skeletal muscles, characterized by a decrease in muscle strength, muscle mass, and physical performance. Although it is usually seen in older individuals, it can also occur in people with certain diseases or who lead a sedentary lifestyle. The European Working Group on Sarcopenia in Older People (EWGSOP) has developed a guideline for the diagnosis of sarcopenia and determination of its severity (Cruz-Jentoft et al., 2019). In line with this guideline, the EWGSOP considers sarcopenia in three basic stages: pre-sarcopenia, sarcopenia, and severe sarcopenia (Cruz-Jentoft et al., 2010). Pre-sarcopenia is the stage in which muscle mass is low but muscle strength or physical performance is not yet affected. Sarcopenia is the stage in which low muscle mass is accompanied by decreased muscle strength or low physical performance. Severe sarcopenia is defined as the most advanced stage in which all these criteria are met (Cruz-Jentoft et al., 2010). Respiratory muscle sarcopenia is defined as muscle fiber atrophy and weakness in the respiratory muscles. The Japanese Respiratory Sarcopenia Study Group defines this condition as whole-body sarcopenia with low respiratory muscle mass, decreased respiratory muscle strength, and/or respiratory dysfunction (Nagano et al., 2021). Kera et al. (2019) evaluated respiratory muscle sarcopenia according to the peak expiratory flow rate value. However, whole-body sarcopenia and respiratory muscle strength are considered important parameters in the definition and diagnosis of respiratory muscle sarcopenia. It is reported that the rate of respiratory muscle sarcopenia is higher in the presence of sarcopenia (Nagano et al., 2021). Sarcopenic respiratory failure is diagnosed in the presence of sarcopenia accompanied by functional disability, while individuals without functional disability but at risk for respiratory muscle sarcopenia are considered "at risk of sarcopenic respiratory failure" (Nagano et al., 2021). Sarcopenia is thought to be associated with insulin resistance and oxidative stress, leading to decreased muscle strength and muscle mass, as well as muscle atrophy (Ding et al., 2019). Respiratory muscles may also be affected in a similar way. Thus, weakening of respiratory muscles may lead to decreased respiratory function and decreased quality of life. In the current literature, studies examining the effects of aging on respiratory muscles are limited. Therefore, determining the potential effects of aging on respiratory muscles and evaluating respiratory muscle sarcopenia in this context may provide an important contribution to the development of new approaches and the literature.


Eligibility criteria: Inclusion Criteria:

* Being 65 years of age or older.
* Being clinically stable
* Being able to adapt to tests (visual, cognitive, cooperative)

Exclusion Criteria:

* Those with neurological and/or musculoskeletal problems that may affect the study
* Presence of severe joint contracture or painful ulcers that may affect muscle strength measurement and walking
* Presence of serious infection or sepsis
* Having a known additional rheumatologic disease diagnosis
* Any stage of cancer

Primary outcomes:
measure: Respiratory Muscle Sarcopenia Assessment
timeFrame: Baseline
Secondary outcomes:
measure: Demographic and Clinical Information
timeFrame: Baseline
measure: Body composition
timeFrame: Baseline
measure: Grip Force Measurement
timeFrame: Baseline
measure: 5 Repetition Sit and Stand Test
timeFrame: Baseline
measure: 4 Meter Walking Speed Test (4MWT)
timeFrame: Baseline
measure: Timed Up and Go Test (TUG)
timeFrame: Baseline
measure: Respiratory muscle strength
timeFrame: Baseline
measure: 6 Minute Walk Test (6MWT):
timeFrame: Baseline
Other outcomes:
Locations:
Study officials:
References: